Progenics Pharmaceuticals, Inc. has entered an agreement with the Centre for Probe Development and Commercialization (CPDC) for the manufacture of Azedra, a targeted radiotherapy candidate in Phase II trials in patients with pheochromocytoma and paraganglioma.   “CPDC, and their host, McMaster University, serve as a model of how collaborative efforts can advance medical discoveries to commercialization,” said Mark Baker, chief executive officer of Progenics. “We believe CPDC ha...